

1 **Comparison of the prevalence and associated factors of chronic kidney disease diagnosed by serum**
2 **creatinine or cystatin C among young people living with HIV in Uganda.**

3 Esther M Nasuuna^{1,2}, Laurie A Tomlinson³, Robert Kalyesubula^{1,4}, Chido Dziva Chikwari^{5,6}, Barbara
4 Castelnuovo¹, Yukari C Manabe^{2,7}, Damalie Nakanjako^{2,8}, Helen A. Weiss⁶

5

6 *1 Non-communicable Diseases Program, Medical Research Council/Uganda Virus Research Institute*
7 *and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe Uganda*

8 *2 Infectious Diseases Institute, Makerere University, College of Health Sciences, Kampala, Uganda*

9 *3. Department of non-Communicable Disease Epidemiology, London School of Hygiene and Tropical*
10 *Medicine, Keppel Street, London, WC1E 7HT, UK*

11 *4. Departments of Physiology and Medicine, Makerere University College of Health Sciences, Kampala,*
12 *Uganda*

13 *5. Biomedical Research and Training Institute, Harare, Zimbabwe*

14 *6. MRC International Statistics and Epidemiology Group, London School of Hygiene & Tropical*
15 *Medicine, London, UK*

16 *7. Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA*

17 *8. Department of Medicine, School of Medicine, College of Health Sciences, Makerere University,*
18 *Kampala, Uganda*

19

20 Corresponding author

21 Esther Nasuuna

22 enasuuna@idi.co.ug

23

24

25

26

27

28

29

30

31

32

33 **Abstract**

34

35 **Introduction**

36 Young people living with HIV (YPLHIV) are at increased risk of developing chronic kidney disease
37 (CKD) which is associated with high mortality and morbidity. Early diagnosis is important to halt
38 progression. We aimed to estimate the prevalence and factors associated with CKD among YPLHIV in
39 Kampala, Uganda, and to compare serum creatinine and cystatin C for early diagnosis of CKD in this
40 population.

41 **Methods**

42 A cross-sectional study with YPLHIV aged 10 to 24 years was conducted in seven HIV clinics.
43 Participants provided a urine and blood sample to measure urinary albumin, proteinuria, serum creatinine

44 and cystatin C levels at baseline and after three months. The estimated glomerular filtration rate (eGFR)
45 was calculated using CKDEPI 2021, Cockcroft-Gault and bedside Schwartz equations using creatinine or
46 cystatin C. The albumin creatinine ratio (ACR) and proteinuria were measured. CKD was defined as
47 either eGFR $<60\text{ml/min/1.73m}^2$ or $<90\text{ml/min/1.73m}^2$ or ACR above 30mg/g on two separate occasions.
48 Univariable and multivariable logistic regression were used to estimate adjusted odds ratios (aOR) and
49 95% confidence intervals (CI) for factors associated with CKD.

50 **Results**

51 A total of 500 participants were enrolled. Most were female (56%; n=280) and aged 10 to 17 years
52 (66.9%; n=335). CKD prevalence ranged from 0-23% depending on the criteria, equation and biomarker
53 used. Cystatin C-based equations estimated higher prevalence of CKD compared to creatinine-based ones.
54 Prevalence of ACR above 30mg/g was 10.1% and of proteinuria 29%. Factors independently associated
55 with CKD were age (aOR=1.42; 95% CI:1.30-1.51) and male sex (aOR=3.02; 95% CI:1.68-5.43).

56 **Conclusion**

57 CKD prevalence among YPLHIV varied substantially depending on definitions used and the current
58 definition would likely lead to missed cases of CKD among YPLHIV. Estimating equations should be
59 validated against measured GFR in YPLHIV and the optimal definition of CKD in this vulnerable
60 population should be revised to optimise detection and opportunities for reducing disease progression.

61

62 **Key words:** prevalence, chronic kidney disease, young people, HIV, Africa, HIV comorbidities

63

64

65 **Introduction**

66 Prevalence of chronic kidney disease (CKD) is increasing globally (1). CKD is defined as abnormalities
67 in kidney structure or function present for three or more months (2). The Global Burden of Disease study

68 estimates CKD prevalence at 9.1% (95% CI 8.5%-9.8%) with geographic variation (3). Studies in Sub-
69 Saharan Africa (SSA) find prevalence ranging from 6%-48% depending on the population, the definitions
70 used, and the measurements taken (4-6).

71 Young people living with HIV (YPLHIV) are at higher risk of CKD than young people not living with
72 HIV (7). CKD risk is associated with high HIV viremia (>4000 copies per ml), severe
73 immunosuppression (CD4 cell count <200 cells/ml), infection with hepatitis C virus, diabetes,
74 hypertension, use of drugs that treat opportunistic infections, and toxicity due to anti-retroviral therapy
75 (ART) from tenofovir disoproxil fumarate (TDF) and indinavir (6, 8-11). Further, YPLHIV in SSA are
76 particularly vulnerable to developing CKD compared to adults living with HIV due to late HIV diagnosis
77 and initiation on ART, poorer adherence to ART complicated by high viremia and low CD4 cell counts
78 (12-14).

79 CKD is associated with high morbidity and mortality as diagnosis is usually delayed, often occurring after
80 kidney failure due to its insidious onset (15). Kidney failure can only be treated with expensive kidney
81 replacement therapies that are not readily available in low and middle-income countries (16). Early
82 diagnosis is important to minimise risk of progression to kidney failure and cardiovascular events (17).

83 Diagnosis of CKD is based on the level of glomerular filtration rate (GFR) and markers of kidney damage
84 such as protein excretion into the urine shown by proteinuria or albuminuria (18). GFR can either be
85 measured directly (mGFR) or estimated (eGFR) with a specific biomarker and one of the estimating
86 equations (19). Most commonly, serum creatinine and cystatin C estimating equations are used to
87 estimate GFR (18, 20). Serum creatinine is widely available and relatively cheap (21) but has limitations
88 as it is influenced by muscle mass, physical activity and general health status (22) as well as high analytic
89 variability (21). Cystatin C is not affected by these conditions as it is produced by most nucleated cells
90 and has uniform generation despite individual differences in people and situations (22-24). However, it is
91 affected by conditions of high inflammation, corticosteroid use and thyroid disease (25). Cystatin C more

92 accurately estimated measured GFR compared to creatinine (26) in a large cohort study done across
93 Uganda, Malawi and South Africa that recommended the use of Cystatin C in African populations (4).
94 Although YPLHIV are at high risk of CKD, little is known about CKD prevalence, the best biomarker to
95 diagnose CKD and factors associated with CKD in this vulnerable group. Therefore, we sought to study
96 this among YPLHIV in Kampala, Uganda.

97 **Methods**

98 **Study design and setting:** This cross-sectional study was conducted in the HIV clinics of seven urban
99 public health facilities from the 12th of April 2023 to 31st January 2024 in Kampala, Uganda. These offer
100 comprehensive HIV care to children (aged below 18 years) and adults (aged 18 years and above).

101 **Study population and sampling:** The study included YPLHIV aged 10-24 years with presumed perinatal
102 HIV infection (defined as being diagnosed with HIV before 10 years of age with self-report of no sexual
103 debut or blood transfusion prior to diagnosis). Pregnant YPLHIV were excluded. Systematic random
104 sampling was used to identify potential participants from all YPLHIV enrolled in the seven HIV clinics
105 from electronic medical records. They were ordered by age at diagnosis and every third person invited to
106 join the study. A sample size of 500 was powered to detect a prevalence of CKD between 16% and 24%.

107 **Study procedures:** Eligible participants were invited to the HIV clinic through a phone call where they
108 were screened, consented, and enrolled. A trained study team member conducted an interview with the
109 participant and completed a questionnaire to record demographic information, symptoms, risk factors and
110 the relevant medical history. Anthropometric measurements (mid-upper arm circumference (MUAC),
111 weight and height) were taken. Weight was assessed using a digital weighing scale, height using a
112 stadiometer and blood pressure (BP) using a digital BP machine with a paediatric cuff for younger
113 participants. Body composition monitoring was conducted using bioimpedance impedance spectroscopy
114 (BIS) to measure body fat, muscle mass and visceral fat. Participants provided a spot urine sample (20
115 mls) as well as 8 ml of venous blood. Urine dipstick was done at the facility to determine proteinuria and

116 other urinary abnormalities. The samples were stored in a cooler box before transfer to the study
117 laboratory on the same day.

118 **Laboratory methods and testing:** In the laboratory, serum creatinine, urinary albumin and cystatin C
119 levels were determined. Those with an albumin creatinine ratio (ACR) >30mg/g or eGFR
120 <60ml/min/1.73m² at baseline were followed-up after three months to confirm the KDIGO guideline-
121 recommended clinical diagnosis of CKD. Cystatin C was measured by particle-enhanced
122 immunoturbidimetric assay on Roche Cobas C311 platform with Tina-quant Cystatin C Gen.2. Creatinine
123 was measured using the enzymatic calorimetric method using an isotope dilution mass spectroscopy
124 (IDMS) traceable standard reference material on the Cobas Integra 400 plus machine with Creatinine Plus
125 Version 2 (CREP2), Roche Diagnostics. The urine albumin was quantified using the
126 immunoturbidimetric assay on the Roche Cobas C311 platform using Tina-quant Albumin Gen2, (Roche
127 Diagnostics). Prior to testing, the machines were calibrated according to manufacturer instructions.
128 Urinalysis by dipstick was done with AYDMED urinalysis Reagent Test Strips (Sungo Europe B.V
129 Amsterdam) to determine presence of urobilinogen, bilirubin, ketones, blood, proteins, nitrites,
130 leucocytes, glucose, specific gravity, pH, and ascorbic acid (27).

131 **Diagnosis of CKD** was based on the kidney disease improving global outcomes (KDIGO) guidelines
132 (28), i.e. 1) markers of kidney damage such as an albumin: creatinine ratio >30mg/g, or 2) eGFR
133 <60ml/min/1.73m², with these abnormalities confirmed with a repeat test after three months (29). To
134 explore CKD definition in this cohort that included children and where chronic disease had affected
135 pubertal development and mean body and muscle mass, we primarily used a range of GFR estimating
136 equations and eGFR cut offs that reflected contemporary practice for adults and children and/or sought to
137 adjust for body size. eGFR_{scr} was estimated using the following creatinine-based equations: CKD
138 Epidemiology collaboration (CKDEPI) 2021 (30), the Bedside Schwartz (31), and Cockcroft-Gault.
139 eGFR_{cystc} was estimated using the following cystatin C-based equations: Schwartz cystatin C (32) and
140 CKDEPI 2012 (33). For completeness prevalence was also estimated using other relevant equations (Full
141 Age Spectrum, CKDEPI40 and Pierce U25), and in combination with ACR and proteinuria. Since a

142 normal GFR is between 90-120 ml/min/1.73m², we also considered a eGFR cut off below
143 90ml/min/1.73m² which is considered stage 2 CKD as abnormal in such a young population (34).
144 **Data management and statistical analysis:** Data were collected in REDCap and analysed with STATA
145 statistical software version 18 (STATA Corp USA). Viral suppression was considered as an HIV viral
146 load below 1000 copies/ml. Hypertension was classified according to the AAP guidelines as being above
147 the 95th percentile for age and sex below 13 years and above 130/80 in those above 13 years (35). Muscle
148 mass was abnormal if below 33.3 for males and 24.3 for females. Social economic status was divided into
149 three using principal component analysis. Demographic data were summarised in percentages or means
150 (standard deviation) and median (interquartile range). The distribution of eGFRs estimated with different
151 equations was shown in a Kernel density plot. CKD prevalence diagnosed by either creatinine or cystatin
152 C was calculated. Univariable logistic regression was used to estimate odds ratios (OR) of factors
153 associated with CKD for each of the five equations used, respectively. All variables with p<0.2 in the
154 univariable model, and a-priori identified variables known to be associated with CKD (age, sex, HIV viral
155 suppression, blood pressure) were then included in a multivariable logistic regression model for each of
156 the five equations.

157 **Ethical considerations**

158 Ethical approval was received from the Uganda Virus Research Institute (UVRI) Research Ethics
159 Committee (reference number GC/127/946), the Uganda National Council of Science and Technology
160 (HS2578ES) and the London School of Hygiene and Tropical Medicine institutional review board
161 (28797). Information about the study appropriate for adults, semi-literate adults and children was
162 provided in an information booklet that was read to the participants and caregivers. All the participants
163 more than 18 years of age provided a written informed consent. Those below 18 years of age provided
164 assent and their caregivers provided written informed consent. If a child refused to provide assent even
165 after their caregiver had provided consent, that child was not enrolled into the study. All participants had
166 the option to withdraw at any point during the research. All participants with suspected CKD were
167 referred to a nephrologist for management.

168 **Results**

169 Of 532 YPLHIV invited to participate, 500 were enrolled as the 32 declined to participate (**Table 1**). The
 170 majority were female (56.0%; n=280), children aged 10-17 years (66.9%; n=335) and living in Kampala
 171 (58.9%; n=295). Females had better nutritional indicators than males - they were less likely to be
 172 underweight (26.4% vs 48.9%; p<0.001), not stunted (85.6% vs 76.9%; p=0.03), and to have normal mid
 173 upper circumference (92.9% vs 87.7%; p=0.05).

174 **Table 1: Demographic characteristics of the study participants by sex.**

	Male	Female	Total
	N=220 (44%)	N=280 (56%)	N=500
Age (mean, SD)	16.5 (3.8)	16.3 (3.5)	16.4 (3.6)
Age category			
Children	143 (65.0)	191 (68.2)	334 (66.8)
Adults	77 (35.0)	89 (31.8)	166 (33.2)
Address			
Kampala	123 (55.9)	171 (61.1)	294 (58.8)
Wakiso	80 (36.4)	99 (35.4)	179 (35.8)
Other districts	17 (7.7)	10 (3.6)	27 (5.4)
Religion			
Christian	158 (71.8)	204 (72.9)	362 (72.4)
Moslem	62 (28.2)	73 (26.1)	135 (27.0)
Other	0 (0.0)	3 (1.1)	3 (0.6)
Social Economic Status			
Lowest	78 (35.5)	100 (35.7)	178 (35.6)
Middle	61 (27.7)	94 (33.6)	155 (31.0)
Highest	81 (36.8)	86 (30.7)	167 (33.4)
School going			
No	58 (26.4)	67 (23.9)	125 (25.0)
Yes	162 (73.6)	213 (76.1)	375 (75.0)
Marital Status			
Married	3 (1.4)	16 (5.7)	19 (3.8)
Never married	217 (98.6)	264 (94.3)	481 (96.2)
Tribe			
Ganda	149 (67.7)	174 (62.1)	323 (64.6)
Other tribes	65 (29.5)	86 (30.7)	151 (30.2)
Non-Ugandan	6 (2.7)	20 (7.1)	26 (5.2)
Weight mean (SD)	48.0 (12.4)	49.4 (12.4)	48.8 (12.4)
Body Mass Index¹			

Normal	173 (79.0)	214 (76.4)	387 (77.6)
Underweight (<18.5kg/m ²)	38 (17.3)	24 (8.6)	62 (12.4)
Overweight (>25kg/m ²)	8 (3.7)	42 (15.0)	50 (10.0)
Stunting**			
Not stunted	123 (76.9)	184 (85.6)	307 (81.9)
Stunted	37 (23.1)	31 (14.4)	68 (18.3)
Mid Upper Arm Circumference²			
Normal	192 (87.7)	260 (92.9)	452 (90.6)
Malnourished	27 (12.3)	20 (7.1)	47 (9.4)
On TDF regimen			
No	61 (27.7)	66 (23.6)	127 (25.4)
Yes	159 (72.3)	214 (76.4)	373 (74.6)
Virally suppressed			
Yes	195 (89.5)	247 (88.5)	442 (88.9)
No	23 (10.5)	32 (11.5)	55 (11.1)
Muscle mass²			
Normal muscle mass	164 (82.0)	235 (87.7)	399 (85.3)
Abnormal muscle mass	36 (18.0)	33 (12.3)	69 (14.7)


175 * Living outside Kampala/Wakiso region. # included those with no religion and those of African traditional religion.

176 **Only those aged less than 19 years. 1 one missing, 2. 32 missing as their measurements were below threshold of
177 the BIS machine.

178 Comparison of serum creatinine and cystatin C

179 The mean serum creatinine (scr) was 0.63 mg/dl (SD 0.15) with a range of 0.29 to 1.2mg/dl. The mean scr
180 was significantly different according to sex, age, presence of stunting or viral suppression. The mean
181 cystatin C was 0.81 mg/dl (SD 0.13) with a range of 0.51 to 1.39 mg/dl. The mean cystatin C was higher
182 in males at 0.86 mg/dl versus 0.78 mg/dl in females but with no other differences (**Supplemental table**
183 **1**). Serum creatinine but not cystatin C was correlated with age and sex (**Figure 1**).

184 **Figure 1: Relationship between serum creatinine and cystatin C and age for males and females**




185

186 Distribution of the eGFR

187 CKDEPI consistently gave higher eGFR readings for both creatinine and cystatin C, and the Schwartz
188 cystatin C equation gave the lowest eGFR values (**Figure 2**).

189 **Figure 2. Kernel density plot showing the distribution of the eGFR according to different estimating**
190 **equations and biomarkers.**




191

192 *Scr serum creatinine, CG cockroft Gault, cys Cystatin C*

193 **Prevalence of CKD using eGFR**

194 CKD prevalence varied according to the eGFR cut-off, and the biomarker used. Using an
195 eGFR<60ml/min/1.73m² cut-off, the highest prevalence was with the Schwartz cystatin C equation
196 (1.4%; 95% CI: 0.5-2.9% at baseline; 0.8%; 95% CI: 0.2-2.1% at 3-month follow-up) and the lowest with
197 the CKDEPI 2021 equation (0%; 95% CI 0-0.07%). Similarly, using eGFR< 90ml/min/1.73m² cut-off,
198 the highest prevalence was with the Schwartz cystatin C equation (58.9%; 95% CI: 54.4-63.3%) and the
199 lowest with CKDEPI (0.6%; 95% CI: 0.01-1.7%) (**Figure 3**). Prevalence using other eGFR equations
200 ranged from 0% to 27.5% (**Supplementary Table 2**).

201 **Figure 3 Prevalence of CKD according to the different estimating equations and biomarkers.**



202

203 **Prevalence of CKD according to eGFR and ACR**

204 All participants were staged according to combined baseline eGFR using cystatin C and ACR to assess
 205 risk of progression (28). Overall, 438 (88.5%) participants had low risk of progression (green), 53
 206 (10.7%) had intermediate risk of progression (yellow) and 4 (0.8%) were at high risk of progression
 207 (orange) (Table 2).

208 **Table 2. All participants' CKD status staged according to estimated GFR from cystatin C and**
 209 **albumin creatinine ratio at baseline.**

eGFR and ACR categories		ACR categories in mg/g			Total numbers
		<30 Normal to mildly increased A1	30-299 Moderately increased A2	>300 Severely increased A3	
eGFR	Stage				
>90	G1	178 (36.0%)	24 (4.9%)	1 (0.2%)	203 (41.1%)
Normal and high					
60-89	G2	258 (52.2%)	24 (4.9%)	2 (0.2%)	284 (57.5%)
Mild reduction					
45-59	G3a	5 (1.0%)	2 (0.4%)	0 (0%)	7 (1.4%)
Mild to moderate reduction					
		441 (89.3%)	50 (10.1%)	3 (0.6%)	494* (100%)

210 eGFR estimated glomerular filtration rate, ACR Albumin creatinine ratio, *6 participants were missing
211 serum creatinine and cystatin C results.

212 **Prevalence of CKD according to markers of kidney damage**

213 Urinalysis showed that 143 (29%) participants had proteinuria on dipstick. Prevalence of proteinuria was
214 similar for those with eGFR>90ml/min/1.73m² and <90ml/min/1.73m² (24.6% vs 31.7% p=0.17). At
215 baseline, 10.1% (50) and at follow up, 3.8% (19) participants had an ACR >30mg/g.

216 **Factors associated with CKD.**

217 Factors associated with CKD varied with the equation and biomarker used for those with an eGFR
218 <90ml/min/1.73m² (**Table 3**) but was largely associated with male sex (with the exception of
219 CKDEPI2021), viral non-suppression (by the cystatin C based equations), increasing age (by the CKDEPI
220 and Bedside Schwartz equations), and being overweight (with the exception of the Cockcroft-Gault
221 equation). CKD was also associated with proteinuria (by the CKDEPI 2012 equation) and being on a
222 TDF-based regimen (by the Bedside Schwartz equation). There was no evidence that CKD was associated
223 with high blood pressure, muscle mass, and ACR.

224 Results were similar when using CKD defined by eGFR<60ml/min/1.73m² (**Supplementary Table 3**).

225 **Table 3. Factors associated with having CKD (eGFR<90ml/min/1.73m²) among study participants** 226 **according to the different estimating equations and biomarkers.**

227 *OR Odds ratio ART Anti-retroviral therapy. N Number, eGFR estimated glomerular filtration rate**

228 *Adjusted for age, sex, blood pressure, viral suppression proteinuria, baseline CD4 T cell count.*

229 **Discussion**

230 This is the first study to compare the prevalence and factors associated with CKD diagnosed by creatinine
231 and cystatin C among YPLHIV in Uganda according to standard guidelines. We found highly variable
232 prevalence depending on the definition, the estimating equation and the biomarker used. This was

233 compounded by the commonly used GFR estimating equations being recommended for adults or children
234 only, despite the highly variable physical and sexual maturity within this important age group where long-
235 term disease management is critical. Using cystatin C eGFR measures consistently gave substantially
236 higher prevalence of CKD: using the Schwartz cystatin equation approximately 60% of YPLHIV had
237 eGFR $<90\text{ml}/\text{min}/1.73\text{m}^2$. While dipstick proteinuria is anticipated in this population largely treated with
238 anti-retroviral drugs, 10% of participants had substantially elevated levels of albuminuria. However, when
239 participants with baseline abnormalities were remeasured at 3 months according to the gold-standard
240 definition, overall prevalence of CKD was much lower.

241 The highest prevalence (59%) using an eGFR cutoff $<90\text{ml}/\text{min}/1.73\text{m}^2$ at baseline which fell to 23% at
242 three months follow-up, was very high. This is similar to a study done in 96 Nigerian YPLHIV aged 15 to
243 29 years which found 53.3% prevalence (36) and a Tanzanian study among 240 YPLHIV aged less than
244 14 years that showed a prevalence of 28% (37). When kidney function was determined by eGFR below
245 $60\text{ml}/\text{min}/1.73\text{m}^2$ on two separate occasions at least three months apart, the prevalence of CKD was
246 0.8%. This is lower than in a study done in Zambia among children living with HIV aged 1 to 18 years
247 that found a prevalence of 3.8% after 3 months (38). However, the children in this study were younger
248 than in this study.

249 Using a eGFR cut off of less than $60\text{ml}/\text{min}/1.73\text{m}^2$ excludes a large proportion of YPLHIV who are
250 already showing signs of impaired kidney function such as an ACR above $30\text{mg}/\text{g}$, proteinuria and
251 hypertension, and who would benefit from early intervention to halt progression of their kidney disease
252 (39). Pottel et al. have shown that clinical manifestations of decreased kidney function in young people
253 start at GFR less than $75\text{ml}/\text{min}/1.73\text{m}^2$; they recommend that the CKD definition should be revised to
254 reflect this (40).

255 KDIGO recommends that screening and surveillance for CKD be tailored to the specific high risk group
256 (41). Our study suggests that using sequential estimation of eGFR over three months excludes YPLHIV at
257 risk of CKD, and might be misleading to the public health response whose goal is to halt progression and

258 to predict those who are in danger of kidney failure or development of cardiovascular complications (41).
259 KDIGO further recommends that screening frequency should be based on the risk profile of the individual
260 and potential to progress (42). YPLHIV have the potential to progress due to the continued insult to the
261 kidney, one abnormal eGFR measurement that shows reduced kidney function should be sufficient for
262 them to be followed up regularly and managed.

263 Estimating GFR in this population was challenging as the different estimating equations and biomarkers
264 gave very different results. This was worse as one transitioned from equations meant for those below 18
265 years to those equations meant for adults above 18 years. The difference in the eGFR was wide even in
266 the same individual. It is difficult to determine the true estimate for CKD among YPLHIV using these
267 estimating equations yet knowing the true estimate is important to plan the public health response for
268 CKD (15). Clinicians who seek to diagnose CKD and plan management may get confused about the true
269 CKD status of an individual. Misdiagnosis and classification of YPLHIV removes the opportunity to
270 intervene early to halt progression to kidney failure (43). However, it is not surprising that each of the
271 estimating equations gave a different prevalence since each estimating equation reflects the characteristics
272 of the population/dataset that was used to develop it (44). There is an urgent need to develop estimating
273 equations for Africans living in Africa.

274 The use of GFR alone doesn't predict progression or mortality risk and other markers of kidney damage
275 such as albuminuria or proteinuria are used (13, 45). When ACR was used, the prevalence was 10.1%.
276 This is lower than that reported among a Tanzanian cohort of YPLHIV aged 1 to 14 years which found a
277 prevalence of 20.1% (37). However, the ACR was determined at a single time point and included younger
278 children. Proteinuria prevalence was 29% which was high in such a young population. Proteinuria is an
279 early marker of HIV associated nephropathy (46) and if persistent, is predictive of CKD status in children
280 (47). However, we measured proteinuria only at baseline and yet two positive out of three readings are
281 used to diagnose persistent proteinuria (41).

282 Cystatin C emerged as a better biomarker than serum creatinine as eGFR calculated from Cystatin C was
283 above CKD stage 1 more consistently for all those that had an increased ACR, proteinuria or hypertension
284 which are markers of abnormal kidney function (18). Cystatin C was recommended by a recent study in
285 three countries (Uganda, Malawi, and South Africa) as the better biomarker in Africans (4). Cystatin C
286 should be recommended for the diagnosis of CKD in YPLHIV as well.

287 We found that age, sex, and HIV viral non-suppression were associated with CKD and that proteinuria,
288 CD4 cell count, blood pressure, and being on a TDF regimen were not associated. A study among
289 perinatally infected YPLHIV in South Africa with a mean age of 12.0 years found sex, but not age or
290 blood pressure were associated with CKD (48). Males were also found to have more CKD than females in
291 a study in Zimbabwe (49). TDF use was also not associated with CKD status in a cohort of American
292 children with CKD (50).

293
294 One of the strengths of this study is that we estimated the eGFR at two different time points more than
295 three months apart as recommended by KDIGO and were able to ascertain those that actually had CKD
296 according to the standard definition of CKD. However, most of the GFR estimating equations and normal
297 serum creatinine have not been validated in YPLHIV in resource-limited settings especially in Africa and
298 this makes it that much harder to determine the abnormal values in YPLHIV (4, 51). This could explain
299 the low correlation between eGFR and the markers of kidney damage found in this study. We determined
300 both markers of kidney damage (albuminuria and proteinuria) and function and could tell YPLHIV that
301 were at risk of CKD progression. The biggest limitation is that we did not measure the GFR using either
302 iohexol or the nuclear tracers ^{99m}Tc -diethylenetriaminepentaacetic acid (DTPA) or ^{51}Cr -EDTA (10) and
303 so we are unable to tell how accurate the eGFR was.

304 **Conclusion**

305 CKD prevalence among YPLHIV in Uganda varies widely depending on the biomarker and definition
306 used. However, there is a substantial prevalence of albuminuria and reduced eGFR suggesting HIV

307 programs should prioritize screening for CKD among YPLHIV. The definition of CKD and best
308 biomarker to use in YPLHIV should be further investigated to optimise detection of those with early
309 abnormalities of kidney function. Estimating equations should be validated against measured GFR in
310 young people to define how best to estimate GFR across older children and young adults in Africa.

311 **List of abbreviations**

ACR	Albumin Creatinine Ratio
AIDS	Acquired Immune Deficiency Syndrome
ALHIV	Adolescents living with HIV
ART	Anti-Retroviral Therapy
BIS	Bioimpedance Spectroscopy
BMI	Body Mass Index
CAKUT	Congenital abnormalities of the Kidney and Urinary Tract
CALHIV	Children and Adolescents living with HIV
CAP	College of American Pathologists
CBC	Complete Blood Count
CD4	Cluster of differentiation 4
CKD	Chronic Kidney Disease
CKD-EPI	Chronic Kidney Disease Epidemiology Collaboration
DM	Diabetes Mellitus
ESKD	End stage kidney disease

EKFC	European Kidney Function Consortium
FAS	Full Age Spectrum
GFR	Glomerular Filtration Rate
HB	Haemoglobin
HIV	Human Immunodeficiency Virus
HIVAN	HIV associated Nephropathy
HIVICK	HIV Immune Complex Kidney Disease
HW	Health Worker
IQR	Interquartile Range
KDIGO	Kidney Disease Improving Global Outcomes
KRT	Kidney replacement therapy
MDRD	Modification of Diet in Renal Disease
MOH	Ministry of Health
NCD's	Non-Communicable Diseases
PCR	Protein Creatinine Ratio
PLHIV	People Living with HIV AIDS
RAAS	Renin Angiotensin Aldosterone Systems
RCT	Randomised Controlled Trials
SSA	Sub Saharan Africa

TB	Tuberculosis
UNAIDS	United Nations Joint AIDS program
USA	United States of America
WHO	World Health Organization
YPLHIV	Young People Living with HIV

312

313 **Declarations**

314 **Ethics approval and consent to participate**

315 Ethical approval was received from the Uganda Virus Research Institute (UVRI) Research Ethics
316 Committee (reference number GC/127/946), the Uganda National Council of Science and Technology
317 (HS2578ES) and the London School of Hygiene and Tropical Medicine institutional review board
318 (28797). Information about the study appropriate for adults, semi-literate adults and children was
319 provided in an information booklet that was read to the participants and caregivers. All the participants
320 more than 18 years of age provided a written informed consent. Those below 18 years of age provided
321 assent and their caregivers provided written informed consent. If a child refused to provide assent even
322 after their caregiver had provided consent, that child was not enrolled into the study. All participants had
323 the option to withdraw at any point during the research. All participants with suspected CKD were
324 referred to a nephrologist for management.

325 **Consent for publication:** Not applicable

326 **Availability of data and materials**

327 The data supporting the findings of this study are openly available in repository
328 <https://datacompass.lshtm.ac.uk/>.

329 **Competing interests**

330 The authors declare no conflict of interest.

331 **Funding**

332 Support for research was provided by Fogarty International Centre, National Institutes of Health (grant
333 #2D43TW009771-06) HIV and co-infections in Uganda. HAW is funded by the UK Medical Research
334 Council (MRC) and the UK Department for International Development (DFID) under the MRC/DFID
335 Concordat agreement (Grant 1: MR/R010161/1). EN, Doctoral Research Fellow, NIHR131273 is funded
336 by the NIHR for this research project. The views expressed in this publication are those of the authors and
337 not necessarily those of the NIHR, NHS or the UK Department of Health and Social Care.

338 **Authors' contributions**

339 EN, LT, RK, CDC, DN, BC, YCM, HW contributed to the conceptualization and design of the study, data
340 collection, analysis, and interpretation. EN, LT, YK drafted the manuscript. CDC, BC, RK, YCM edited
341 the draft manuscript. HW was responsible for the overall supervision of this work. All authors reviewed
342 and approved the manuscript before submission for publication.

343 **Acknowledgements**

344 The authors acknowledge the health workers and peers at the implementing facilities where this data was
345 collected. The HIV program at the participating health facilities is supported by the President's
346 Emergency Plan for AIDS Relief (PEPFAR) through CDC.

347

348

349 **References**

350 1. Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. *Kidney International*
351 *Supplements*. 2022;12(1):7-11.

352 2. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease:

- 353 Evaluation, classification, and stratification. *American Journal of Kidney Disease* 39:S1–S266. 2002.
- 354 3. Bikbov B, Purcell CA, Levey AS, Smith M, Abdoli A, Abebe M, et al. Global, regional, and
355 national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of
356 Disease Study 2017. *The Lancet*. 2020;395(10225):709-33.
- 357 4. Fabian J, Kalyesubula R, Mkandawire J, Hansen CH, Nitsch D, Musenge E, et al. Measurement
358 of kidney function in Malawi, South Africa, and Uganda: a multicentre cohort study. *The Lancet Global
359 Health*. 2022;10(8):e1159-e69.
- 360 5. Fabian J, George JA, Etheredge HR, van Deventer M, Kalyesubula R, Wade AN, et al. Methods
361 and reporting of kidney function: a systematic review of studies from sub-Saharan Africa. *Clinical
362 Kidney Journal*. 2019;12(6):778-87.
- 363 6. Naicker S, Fabian J. Risk factors for the development of chronic kidney disease with HIV/AIDS.
364 *Clin Nephrol*. 2010;74 Suppl 1:S51-6.
- 365 7. Frigati LJ, Ameyan W, Cotton MF, Gregson CL, Hoare J, Jao J, et al. Chronic comorbidities in
366 children and adolescents with perinatally acquired HIV infection in sub-Saharan Africa in the era of
367 antiretroviral therapy. *The Lancet Child & Adolescent Health*. 2020;4(9):688-98.
- 368 8. Jotwani V, Atta MG, Estrella MM. Kidney Disease in HIV: Moving beyond HIV-Associated
369 Nephropathy. *Journal of the American Society of Nephrology*. 2017;28(11):3142-54.
- 370 9. Kalyesubula R, Wearne N, Semitala FC, Bowa K. HIV-associated renal and genitourinary
371 comorbidities in Africa. *Journal of acquired immune deficiency syndromes (1999)*. 2014;67 Suppl 1:S68-
372 78.
- 373 10. Purswani MU, Chernoff MC, Mitchell CD, Seage GR, Zilleruelo G, Abitbol C, et al. Chronic
374 kidney disease associated with perinatal HIV infection in children and adolescents. *Pediatric nephrology*.
375 2012;27(6):981-9.
- 376 11. Bhimma R, Purswani MU, Kala U. Kidney disease in children and adolescents with perinatal
377 HIV infection. *Journal of the International AIDS Society*. 2013;16(1):18596.
- 378 12. Innes S, Patel K. Non-communicable diseases in adolescents with perinatally-acquired HIV-1
379 infection in high-and low-income settings. *Current opinion in HIV and AIDS*. 2018;13(3):187.
- 380 13. Bunupuradah T, Phupitakphol T, Sophonphan J, Prasitsuebsai W, Anugulruengkitt S,
381 Jantarabenjakul W, et al. Prevalence of persistent renal dysfunction in perinatally HIV-infected Thai
382 adolescents. *Pediatr Infect Dis J*. 2018;37(1):66-70.
- 383 14. Bernheimer JM, Patten G, Makeleni T, Mantangana N, Dumile N, Goemaere E, et al. Paediatric
384 HIV treatment failure: a silent epidemic. *J Int AIDS Soc*. 2015;18:20090.
- 385 15. Stanifer JW, Muiru A, Jafar TH, Patel UD. Chronic kidney disease in low-and middle-income
386 countries. *Nephrology Dialysis Transplantation*. 2016;31(6):868-74.
- 387 16. Kalyesubula R, Makanga G, Gyagenda JO, Atuhe D, Kansime G, Kiggundu D, et al. Nephrology
388 in Uganda. *Nephrology Worldwide*. 2021:75-83.

- 389 17. George C, Mogueo A, Okpechi I, Echouffo-Tcheugui JB, Kengne AP. Chronic kidney disease in
390 low-income to middle-income countries: the case for increased screening. *BMJ Glob Health*.
391 2017;2(2):e000256.
- 392 18. Lopez-Giacoman S, Madero M. Biomarkers in chronic kidney disease, from kidney function to
393 kidney damage. *World journal of nephrology*. 2015;4(1):57.
- 394 19. Levey AS, Titan SM, Powe NR, Coresh J, Inker LA. Kidney Disease, Race, and GFR Estimation.
395 *Clinical Journal of the American Society of Nephrology*. 2020;15(8):1203-12.
- 396 20. Carrara F, Gaspari F. GFR measured by iohexol: the best choice from a laboratory perspective.
397 *Journal of Laboratory and Precision Medicine*. 2018;3.
- 398 21. Kashani K, Rosner MH, Ostermann M. Creatinine: From physiology to clinical application.
399 *European Journal of Internal Medicine*. 2020;72:9-14.
- 400 22. Shlipak MG, Mattes MD, Peralta CA. Update on cystatin C: incorporation into clinical practice.
401 *American Journal of Kidney Diseases*. 2013;62(3):595-603.
- 402 23. Seape T, Gounden V, van Deventer HE, Candy GP, George JA. Cystatin C- and creatinine-based
403 equations in the assessment of renal function in HIV-positive patients prior to commencing Highly Active
404 Antiretroviral Therapy. *Annals of Clinical Biochemistry*. 2016;53(1):58-66.
- 405 24. Mauss S, Berger F, Kuschak D, Henke J, Hegener P, Wolf E, et al. Cystatin C as a marker of
406 renal function is affected by HIV replication leading to an underestimation of kidney function in HIV
407 patients. SAGE Publications Sage UK: London, England; 2008.
- 408 25. Mian AN, Schwartz GJ. Measurement and estimation of glomerular filtration rate in children.
409 *Advances in chronic kidney disease*. 2017;24(6):348-56.
- 410 26. Shlipak MG, Matsushita K, Ärnlöv J, Inker LA, Katz R, Polkinghorne KR, et al. Cystatin C
411 versus creatinine in determining risk based on kidney function. *New England Journal of Medicine*.
412 2013;369(10):932-43.
- 413 27. Queremel Milani DA, Jialal I. *Urinalysis*: StatPearls Publishing, Treasure Island (FL); 2020 2020.
- 414 28. Levin A, Stevens PE, Bilous RW, Coresh J, De Francisco AL, De Jong PE, et al. Kidney Disease:
415 Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for
416 the evaluation and management of chronic kidney disease. *Kidney international supplements*.
417 2013;3(1):1-150.
- 418 29. Levey AS, Eckardt K-U, Dorman NM, Christiansen SL, Cheung M, Jadoul M, et al.
419 Nomenclature for kidney function and disease: executive summary and glossary from a Kidney Disease:
420 Improving Global Outcomes (KDIGO) consensus conference. *Kidney Diseases*. 2020;6(5):309-17.
- 421 30. Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, et al. New Creatinine- and
422 Cystatin C–Based Equations to Estimate GFR without Race. *New England Journal of Medicine*.
423 2021;385(19):1737-49.

- 424 31. Schwartz GJ, Munoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, et al. New equations to
425 estimate GFR in children with CKD. *Journal of the American Society of Nephrology: JASN*.
426 2009;20(3):629.
- 427 32. Schwartz GJ, Schneider MF, Maier PS, Moxey-Mims M, Dharnidharka VR, Warady BA, et al.
428 Improved equations estimating GFR in children with chronic kidney disease using an
429 immunonephelometric determination of cystatin C. *Kidney International*. 2012;82(4):445-53.
- 430 33. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, et al. Estimating
431 glomerular filtration rate from serum creatinine and cystatin C. *New England Journal of Medicine*.
432 2012;367(1):20-9.
- 433 34. Levey AS, Coresh J. Chronic kidney disease. *The Lancet*. 2012;379(9811):165-80.
- 434 35. Flynn JT, Falkner BE. New Clinical Practice Guideline for the Management of High Blood
435 Pressure in Children and Adolescents. *Hypertension (Dallas, Tex : 1979)*. 2017;70(4):683-6.
- 436 36. Okafor UH, Unuigbo EI, Chukwuonye E. Prevalence and clinical and laboratory characteristics of
437 kidney disease in anti-retroviral-naive human immunodeficiency virus-infected patients in South-South
438 Nigeria. *Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center
439 for Organ Transplantation, Saudi Arabia*. 2016;27(1):129-34.
- 440 37. Fredrick F, Francis JM, Ruggajo PJ, Maro EE. Renal abnormalities among HIV infected children
441 at Muhimbili National Hospital (MNH)-Dar es Salaam, Tanzania. *BMC nephrology*. 2016;17:30.
- 442 38. Zimba KM. Prevalence and factors associated with renal dysfunction in HIV positive paediatric
443 patients on highly active antiretroviral therapy at the paediatric centre of excellence of the university
444 teaching hospital, in Lusaka, Zambia. *Pediatric Nephrology*. 2016;31(10):1778.
- 445 39. Uhlig K, Johnson CA, Levey AS. New guidelines spell out approach to chronic kidney disease:
446 early diagnosis of chronic kidney disease widens the window of opportunity to put effective treatments to
447 work. Recent National Kidney Foundation clinical practice guidelines provide a simple definition, a
448 practical staging system, and a stage-appropriate action plan. *Patient Care*. 2003;37(7):38-45.
- 449 40. Pottel H, Hoste L, Delanaye P. Abnormal glomerular filtration rate in children, adolescents and
450 young adults starts below 75 mL/min/1.73 m². *Pediatric Nephrology*. 2015;30:821-8.
- 451 41. Levey A, Atkins R, Coresh J, Cohen E, Collins A, Eckardt K-U, et al. Chronic kidney disease as
452 a global public health problem: approaches and initiatives—a position statement from Kidney Disease
453 Improving Global Outcomes. *Kidney international*. 2007;72(3):247-59.
- 454 42. Shlipak MG, Tummalapalli SL, Boulware LE, Grams ME, Ix JH, Jha V, et al. The case for early
455 identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving
456 Global Outcomes (KDIGO) Controversies Conference. *Kidney international*. 2021;99(1):34-47.
- 457 43. Bhimma R. HIV-Related Kidney Diseases. In: Bobat R, editor. *HIV Infection in Children and
458 Adolescents*. Cham: Springer International Publishing; 2020. p. 143-52.
- 459 44. Miller WG. Perspective on New Equations for Estimating Glomerular Filtration Rate. *Clinical
460 Chemistry*. 2021;67(6):820-2.

- 461 45. Bökenkamp A. Proteinuria—take a closer look! *Pediatric Nephrology*. 2020;35(4):533-41.
- 462 46. Palau L, Menez S, Rodriguez-Sanchez J, Novick T, Delsante M, McMahon BA, et al. HIV-
463 associated nephropathy: links, risks and management. *HIV AIDS (Auckl)*. 2018;10:73-81.
- 464 47. Beng H, Rakhmanina N, Moudgil A, Tuchman S, Ahn S-Y, Griffith C, et al. HIV-associated
465 CKDs in children and adolescents. *Kidney international reports*. 2020;5(12):2292-300.
- 466 48. Frigati L, Mahtab S, Nourse P, Ray P, Perrazzo S, Machedez T, et al. Prevalence of risk
467 factors for chronic kidney disease in South African youth with perinatally acquired HIV. *Pediatric
468 nephrology (Berlin, Germany)*. 2018;34(2):313-8.
- 469 49. Byers BW, Drak D, Shamu T, Chimbetete C, Dahwa R, Gracey DM. Assessing renal impairment
470 in treatment-naïve adolescents living with HIV commencing antiretroviral therapy in Zimbabwe. *AIDS*.
471 2023;37(5):789-94.
- 472 50. Purswani M, Patel K, Kopp JB, Seage GR, 3rd, Chernoff MC, Hazra R, et al. Tenofovir treatment
473 duration predicts proteinuria in a multiethnic United States Cohort of children and adolescents with
474 perinatal HIV-1 infection. *Pediatr Infect Dis J*. 2013;32(5):495-500.
- 475 51. Swanepoel CR, Atta MG, D'Agati VD, Estrella MM, Fogo AB, Naicker S, et al. Kidney disease
476 in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes
477 (KDIGO) Controversies Conference. *Kidney international*. 2018;93(3):545-59.
- 478

	eGFR<90ml/min/1.73m ² from Cystatin C based Equations				eGFR<90ml/min/1.73m ² from Serum Creatinine Based Equations					
	CKD EPI 2012 (n=36/494)		Schwartz Cystatin (n=291/494)		CKDEPI 2021 (n=6/494)		Bedside Schwartz (n=140/494)		Cockcroft Gault (n=68/493)	
	Unadjusted OR	Adjusted OR*	Unadjusted OR	Adjusted OR	Unadjusted OR	Adjusted OR	Unadjusted OR	Adjusted OR	Unadjusted OR	Adjusted OR
Age in years	1.14 (1.03-1.25)	1.13 (1.01-1.27)	0.98 (0.94-1.04)	0.99 (0.94-1.04)	1.50 (1.13-1.98)	1.45 (1.01-2.14)	1.40 (1.30-1.51)	1.42 (1.28-1.58)	0.99 (0.94-1.04)	1.08 (0.96-1.22)
Age categorized										
>18	1	1	1		1		1		1	
<18	0.47 (0.33-0.92)		1.06 (0.73-1.55)		0.09 (0.01-0.83)		0.17 (0.11-0.26)		0.89 (0.52-1.52)	0.63 (0.23-1.77)
Sex										
Females	1		1		1		1		1	
Males	2.42 (1.2-4.92)	2.84 (1.27-6.31)	3.21 (2.18-4.71)	3.13 (2.12-4.65)	0.64 (0.12-3.52)	0.75 (0.11-4.92)	2.22 (1.49-3.32)	3.02 (1.68-5.43)	3.21 (2.18-4.71)	0.32 (0.16-0.60)
Blood pressure										
Normal	1	1	1		1	1	1	1	1	1
Elevated	0.59 (0.17-1.98)	0.41 (0.86-1.90)	1.69 (0.95-2.98)	1.42 (0.79-2.59)	0.07 (0.00-0.63)	0.35 (-.)	1.19 (0.66-2.17)	1.02 (0.45-2.31)	0.41 (0.21-0.78)	0.26 (0.08-0.80)
Hypertensive	0.98 (0.39-2.45)	0.69 (0.26-1.89)	1.25 (0.76-2.06)	1.14 (0.67-1.94)	0.45 (0.04-4.04)	1.61 (0.24,10.63)	2.42 (1.46-4.02)	1.69 (0.89-3.29)	0.73 (0.35-1.50)	0.58 (0.18-1.86)
Viral suppression										
Suppressed	1	1	1	1	1		1		1	
Non suppressed	3.11 (1.38-7.04)	3.27 (1.29-8.32)	2.09 (1.11-3.97)	2.29 (1.18-4.44)	1.01 (0.00-7.12)	0.92 (.,)	0.42 (0.19-0.91)	0.34 (0.13-0.89)	0.63 (0.24-1.64)	0.61 (0.21-1.74)
CD4 T cell count at baseline										
>500	1	1	1		1		1		1	
200-500	2.3 (0.98-5.38)	1.41 (0.55-3.59)	1.54 (0.96-2.48)		1.52 (0.03-29.58)		1.86 (1.03-3.04)	0.66 (0.35-1.25)	1.08 (0.56-2.10)	
<200	3.84 (1.5-9.38)	2.59 (0.97-6.92)	1.76 (0.96-3.22)		5.34 (0.38-75.78)		1.89 (1.04-3.46)	0.65 (0.29-1.44)	1.22 (0.56-2.68)	
Social Economic Status										
Least	1		1		1		1		1	
Middle	1.03 (0.42-2.49)		0.96 (0.62-1.49)		2.28 (0.81-2.21)		1.34 (0.62-1.49)	1.32 (0.69-2.51)	1.04 (0.56-1.92)	

Highest	1.47 (0.66-3.31)	1.15 (0.74-1.78)	1.85 (1.15-2.99)	1.15 (0.75-1.78)	1.40 (0.75-2.64)	0.81 (0.43-1.52)	
Body Mass Index							
Normal	1	1	1	1		1	1
Underweight	1.69 (0.82-3.43)	1.36 (0.92-2.01)	0.29 (0.00-2.30)	0.31 (0.18-0.51)	0.74 (0.32-1.68)	4.03 (2.29-7.09)	7.23 (3.33-15.7)
Overweight	1.27 (0.35-4.56)	1.24 (0.63-2.43)	3.11 (0.27-22.51)	1.81 (0.94-3.51)	1.98 (0.68-5.74)	0.19 (0.00-1.12)	
Weight in Kg	1.02 (0.99-1.04)	1.01 (0.99-1.02)	-	1.06 (1.04-1.09)	0.99 (0.96-1.04)		
Stunting							
Not stunted	1	1	1	1		1	
Stunted	1.42 (0.50-4.02)	0.88 (0.52-1.51)	-	0.67 (0.31-1.43)		1.81 (0.87-3.73)	
Mid Upper Arm Circumference							
Normal	1	1	1	1		1	
Malnourished	1.64 (0.60-4.44)	0.74 (0.40-1.36)	-	0.43 (0.18-0.98)	0.82 (0.29-2.39)	4.05 (2.07-7.93)	1.81 (0.79-4.13)
Muscle mass							
Normal	1	1	1	1		1	
Abnormal	1.10 (0.41-2.98)	1.28 (0.76-2.18)	3.89 (0.64-23.66)	1.44 (0.84-2.48)		0.96 (0.45-2.05)	
Proteinuria							
Negative	1	1	1	1		1	
Positive	3.40 (1.7-6.78)	3.71 (1.75-7.88)	1.44 (0.96-2.15)	1.22 (0.11-8.69)	1.49 (0.98-2.27)	1.12 (0.64-1.95)	
Albumin creatinine ratio							
<30	1	1					
>30	1.74 (0.69-4.4)	0.76 (0.43-1.34)	1.67 (0.19-14.6)	0.89 (0.47-1.71)			
On Tenofovir based regimen							
No	1	1	1	1		1	
Yes	1.45 (0.62-3.41)	0.97 (0.64-1.46)	1.72 (0.19-14.88)	3.22 (1.85-5.61)	1.87 (0.94-3.73)	0.63 (0.36-1.08)	
Duration on ART in years							
< 5	1	1	1	1		1	

6 to 10	0.49 (0.17-1.43)	0.79 (0.46-1.39)	0.75 (-,-)	0.92 (0.49-1.71)	0.78 (0.37-1.61)
>10	1.11 (0.43-2.89)	1.12 (0.64-1.98)	1.27 (-,-)	1.31 (0.71-2.42)	0.62 (0.11-0.39)

